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dIFFErEnTIal dIagnoSIS
The differential was broad including septic shock, toxin 
ingestion, cardiogenic shock, and intracranial abnormality. 
Drug toxicity was ruled out as her urine drug screen and 
alcohol level were negative.  Severe sepsis was ruled out when 
cultures (urine, blood, bronchoalveolar lavage) were negative. 
CT chest, abdomen, and pelvis did not show any source of 
infection.  CT head was within normal limits.  A transthoracic 
echocardiogram did not show significant abnormalities.  Given 
her elevated anion gap metabolic acidosis with concomitant 
osmolar gap, a diagnosis of MALA was made.
ouTCoME and Follow uP
Patient was intubated and admitted to the medical 
intensive care unit.  She was empirically started on broad-
spectrum antibiotics, stress dose steroids, intravenous 
fluids, and vasopressors for presumed septic shock.  Given 
her low bicarbonate level, a bicarbonate drip was started, 
and nephrology was consulted for acute renal failure 
and metabolic acidosis management.  The nephrology 
team initiated her on continuous veno-venous hemofil-
tration (CVVH) therapy.  She had 3 days of CVVH, after 
which she was transitioned to intermittent hemodialysis. 
Patient’s urine output gradually improved throughout her 
hospital stay.  Upon discharge, she was alert, oriented, and 
conversing appropriately.
dISCuSSIon
Metformin is renally cleared and therefore accumulates in 
states of decreased creatinine clearance.  It also inhibits 
mitochondrial electron transport, thereby increasing 
anaerobic metabolism and lactate production.1  It has 
been proposed that in acute kidney injury, metformin 
levels accumulate, contributing to worsening lactic 
acidosis, which further compounds nausea and vomiting, 
and thereby reducing renal perfusion.2  The incidence of 
MALA is thought to be 1-5 cases per 100,000 patient years 
but can be as high as 30 cases per 100,000 patient years.3 
Mortality ranges from 25-50%.4
The 5 characteristics highly suggestive of MALA are: severe 
acidemia (pH < 7.1) with an anion gap greater than 20 
mEq/L (normal anion gap ≤ 12 mEq/L), very low serum 
InTroduCTIon
Metformin is a first line oral medication for diabetes mellitus 
shown to decrease cardiovascular morbidity and mortality. 
Though the prevalence of metformin-associated lactic 
acidosis (MALA) is low, mortality is high, ranging from 
25-50%.  Therefore, it presents a diagnostic challenge 
that is critical to identify, particularly in patients with renal 
impairment at baseline.  Traditionally patients with creatinine 
greater than 1.5 mg/dL have been excluded from using 
metformin; however, metformin might be acceptable in 
some patients with chronic kidney disease (CKD).
CaSE PrESEnTaTIon:
A 69 year old female with a past medical history of diabetes 
mellitus, hypertension, breast cancer, and no chronic 
kidney disease was sent to the hospital by her rehabilitation 
facility secondary to her being found unresponsive.  This 
was in the presence of decreased appetite and impaired 
mobility limiting her ability to feed herself in the 2 weeks 
prior to hospital admission.  Her medications included 
metformin, insulin glargine, anastrazole, and hydrochlo-
rothiazide.  She had nausea and vomiting the night prior 
to admission.  Despite her decreased oral intake, she 
continued taking her full dose of metformin and insulin 
throughout that two week period.
On arrival to the emergency room, her vitals were rectal 
temperature 90.6° F, heart rate 66 beats per minute, 
blood pressure 60/40 mmHg, respiratory rate 25 breaths 
per minute, and oxygen saturation 88% on room air.  Her 
Glasgow Coma Scale was 2 with physical exam findings 
significant for limited withdrawal to noxious stimuli.  Her 
initial labs were significant for bicarbonate of 2 mEq/L 
(normal range 24-32 mEq/L), potassium of 6.7 mEq/L 
(normal range 3.5-5.0 mEq/L), blood urea nitrogen of 110 
mg/dL (normal range 7-26 mg/dL), creatinine of 9.7 mg/
dL (normal range 0.7-1.4mg/dL) with a baseline of 0.7 mg/
dL 2 months ago, and lactate of 26 mmol/L (normal range 
0.5-2.2 mmol/L).  A venous blood gas was significant for a 
pH of 6.65.  Plasma metformin level was not available.  
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removed by renal replacement therapy.10 Furthermore, 
though our patient did not have any CKD at baseline, she 
should have been counseled on stopping her metformin 
during periods of poor appetite or dehydration.   Physicians 
need to be comfortable and knowledgeable with using 
metformin alongside medications that interfere with renal 
hemodynamic regulation such as angiotensin-converting-
enzyme inhibitors, aldosterone receptor blockers, and 
nonsteroidal anti-inflammatory drugs.3
KEy PoInTS
Metformin is currently a first-line agent in the management 
of diabetes.  Though it can cause metformin-associated 
lactic acidosis, the prevalence is relatively low.  High clinical 
suspicion is, however, important.  In those taking metformin 
and presenting with lactate greater than 15 mmol/L and pH 
less than 7, MALA must be strongly considered.  To prevent 
MALA, patients on metformin should be counseled on its use 
in states of potential kidney injury such as volume depletion 
as was the case in our patient.  Overall, patients who have 
MALA should receive aggressive resuscitation methods 
including fluid repletion, airway protection, vasopressors, 
intravenous bicarbonate, and/or renal replacement therapy 
depending on the severity of the acidosis.
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bicarbonate (7 +/-  4 mEq/L), markedly elevated lactic acid 
(12.4 +/- 8 mmol/L), history of metformin ingestion, and 
history of renal insufficiency.1,5  With infectious and other 
drug toxicities ruled out in this patient, MALA was the most 
likely cause of her lactic acidosis as the patient met all 5 
aforementioned points.  We propose that this patient, in 
the presence of decreased oral intake in the weeks prior 
to her presentation, developed acute kidney injury, which 
decreased her ability to clear metformin.  Consequently, 
she started developing lactic acidosis, which likely 
worsened any nausea or vomiting, further exacerbating 
her acute renal failure leading to anuria.
Given the lack of randomized control trials in the study of 
MALA, much of the existing literature on MALA are case 
series, retrospective studies, and observations.  The goal 
in the acute management of MALA is to provide airway, 
breathing, and circulatory support and to correct the 
underlying acidosis with possible intravenous bicarbonate 
and/or renal replacement therapy.6
A retrospective analysis study compared cases of severe 
acidosis with pH < 7.0 secondary to MALA and lactic 
acidoses of other origins. Despite the pH being lower in the 
former group, the mortality was 100% in the latter group as 
compared to 50% in the former.  This shows that despite a 
greater degree of acidosis and renal failure in MALA patients, 
early recognition and aggressive medical therapy including 
renal replacement therapy improves the survival.7
A recently published retrospective study looked at the 
incidence of MALA in those with and without impaired 
renal function.  The 77,601 identified patients were divided 
into different groups based on glomerular filtration rate 
(GFR): normal, mildly reduced, moderately reduced, or 
severely reduced.   They found an incidence of 10.37 per 
100,000 patient years.  What is more significant is that they 
did not find a significant difference in the development of 
MALA among the 4 groups.8  This calls for more awareness 
amongst general internists such that impending signs 
of MALA should be recognized earlier. A recent review 
article suggests that given the mild association between 
metformin and lactic acidosis, metformin can be used in 
those with impaired renal function but should be dosed by 
GFR secondary to metformin’s varied benefits.9 
Prognosis of MALA is more favorable than other etiologies 
of lactic acidosis.1,10  This may be secondary to the absence 
of a critical underlying condition causing lactic acidosis 
such as severe ischemia.  Rather the lactic acidosis is a result 
of toxic drug accumulation, which can be successfully 
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